WO2007146957A3 - Ror1 as a therapeutic target for lung cancer - Google Patents

Ror1 as a therapeutic target for lung cancer Download PDF

Info

Publication number
WO2007146957A3
WO2007146957A3 PCT/US2007/071037 US2007071037W WO2007146957A3 WO 2007146957 A3 WO2007146957 A3 WO 2007146957A3 US 2007071037 W US2007071037 W US 2007071037W WO 2007146957 A3 WO2007146957 A3 WO 2007146957A3
Authority
WO
WIPO (PCT)
Prior art keywords
ror1
lung cancer
therapeutic target
tumor growth
compounds
Prior art date
Application number
PCT/US2007/071037
Other languages
French (fr)
Other versions
WO2007146957A2 (en
Inventor
Markus Warmuth
Karin Foster
Original Assignee
Irm Llc
Markus Warmuth
Karin Foster
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Markus Warmuth, Karin Foster filed Critical Irm Llc
Publication of WO2007146957A2 publication Critical patent/WO2007146957A2/en
Publication of WO2007146957A3 publication Critical patent/WO2007146957A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Abstract

This invention relates to the use of Ror1-antagonizing compounds to inhibit tumor growth and to treat cancer (e.g., lung cancer). The invention also provides methods of using Ror1 to screen for compounds that inhibit tumor growth.
PCT/US2007/071037 2006-06-13 2007-06-12 Ror1 as a therapeutic target for lung cancer WO2007146957A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81349906P 2006-06-13 2006-06-13
US60/813,499 2006-06-13

Publications (2)

Publication Number Publication Date
WO2007146957A2 WO2007146957A2 (en) 2007-12-21
WO2007146957A3 true WO2007146957A3 (en) 2008-11-13

Family

ID=38698841

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/071037 WO2007146957A2 (en) 2006-06-13 2007-06-12 Ror1 as a therapeutic target for lung cancer

Country Status (1)

Country Link
WO (1) WO2007146957A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9523695B2 (en) 2011-01-14 2016-12-20 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126894A2 (en) * 2008-04-11 2009-10-15 Massachusetts Eye And Ear Infirmary Methods and compositions for the diagnosis and treatment of angiogenic disorders
US8710022B2 (en) 2008-07-18 2014-04-29 National University Corporation Nagoya University Cell proliferation inhibitor
CA2759733C (en) * 2009-04-23 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human ror1 antibodies
EP2462951B1 (en) * 2009-07-09 2014-09-03 Cancer Institute, Chinese Academy of Medical Sciences Use of two microrna moleculars in lung cancer prognosis and medicine preparation
US20120282177A1 (en) * 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
US9150647B2 (en) 2009-12-18 2015-10-06 Kancera Ab Biological inhibitors of ROR1 capable of inducing cell death
GB2476293A (en) * 2009-12-18 2011-06-22 Biolnvent Internat Ab Therapeutic inhibition of ROR-1
CN102169121B (en) * 2010-02-25 2013-12-04 北京诺赛基因组研究中心有限公司 New application of human kinase SBK1 (SH3-binding domain kinase 1)
US9242014B2 (en) 2010-06-15 2016-01-26 The Regents Of The University Of California Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof
US9228023B2 (en) 2010-10-01 2016-01-05 Oxford Biotherapeutics Ltd. Anti-ROR1 antibodies and methods of use for treatment of cancer
WO2012090939A1 (en) * 2010-12-27 2012-07-05 国立大学法人名古屋大学 Method for suppressing receptor tyrosine kinase-mediated prosurvival signaling in cancer cells
CA2881966C (en) 2012-08-24 2020-10-06 The Regents Of The University Of California Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
CA2963692A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1
EP3368574A1 (en) 2015-10-30 2018-09-05 NBE-Therapeutics AG Anti-ror1 antibodies
RU2766190C2 (en) 2016-01-20 2022-02-09 Дзе Скриппс Рисерч Инститьют Compositions of antibodies against ror1 and corresponding methods
CA3029003A1 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
WO2019030223A1 (en) 2017-08-07 2019-02-14 Nbe-Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004048540A2 (en) * 2002-11-25 2004-06-10 Exelixis, Inc. Mracs as modifiers of the rac pathway and methods of use
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
WO2004094641A2 (en) * 2003-04-16 2004-11-04 Wyeth A novel method of modulating bone-realted activity
WO2005100605A1 (en) * 2004-04-06 2005-10-27 The Regents Of The University Of California Orphan receptor tyrosine kinase as a target in breast cancer
WO2007051077A2 (en) * 2005-10-28 2007-05-03 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116330A1 (en) * 2001-04-27 2004-06-17 Kenichiro Naito Preventive/therapeutic method for cancer
WO2004048540A2 (en) * 2002-11-25 2004-06-10 Exelixis, Inc. Mracs as modifiers of the rac pathway and methods of use
WO2004094641A2 (en) * 2003-04-16 2004-11-04 Wyeth A novel method of modulating bone-realted activity
WO2005100605A1 (en) * 2004-04-06 2005-10-27 The Regents Of The University Of California Orphan receptor tyrosine kinase as a target in breast cancer
WO2007051077A2 (en) * 2005-10-28 2007-05-03 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHOI JAMES ET AL: "Transcriptosome profiling of B-CLL identifies WNT-3A and ROR1 as an autocrine mechanism in cell survival.", BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), & 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 598A - 599A, XP002490901, ISSN: 0006-4971 *
FUKUDA TETSUYA ET AL: "Immune therapy for chronic lymphocytic leukemia induces the antibody response against a novel tumor-associated antigen, the orphan tyrosine kinase receptor ROR1", BLOOD, vol. 106, no. 11, Part 1, November 2005 (2005-11-01), & 47TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; ATLANTA, GA, USA; DECEMBER 10 -13, 2005, pages 834A - 835A, XP009104045, ISSN: 0006-4971 *
KATOH MASARU: "WNT/PCP signaling pathway and human cancer (review)", ONCOLOGY REPORTS, vol. 14, no. 6, December 2005 (2005-12-01), pages 1583 - 1588, XP009104214, ISSN: 1021-335X *
REDDY USHA R ET AL: "Human neural tissues express a truncated Ror1 receptor tyrosine kinase, lacking both extracellular and transmembrane domains", ONCOGENE, vol. 13, no. 7, 1996, pages 1555 - 1559, XP009103917, ISSN: 0950-9232 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9523695B2 (en) 2011-01-14 2016-12-20 The Regents Of The University Of California Therapeutic antibodies against ROR-1 protein and methods for use of same

Also Published As

Publication number Publication date
WO2007146957A2 (en) 2007-12-21

Similar Documents

Publication Publication Date Title
WO2007146957A3 (en) Ror1 as a therapeutic target for lung cancer
WO2006017295A3 (en) Tetrapeptide analogs
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
WO2007127010A3 (en) Diarylthiohydantoin compounds
WO2007013950A3 (en) Combination therapy of her expressing tumors
HK1131608A1 (en) Pyridinone compounds
WO2008031551A3 (en) Non-neuroendocrine cancer therapy
WO2008097561A8 (en) Oxabicycloheptanes and oxabicycloheptenes, their preparation and use
WO2008137633A3 (en) Methods of modulating cellular homeostatic pathways and cellular survival
WO2007087395A3 (en) UNSATURATED mTOR INHIBITORS
WO2008085794A3 (en) Methods and compositions related to clot binding compounds
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2009002947A3 (en) Compounds and peptides that bind the trail receptor
WO2007009007A3 (en) Methods of treatment using hydroquinone ansamycins
WO2009070294A3 (en) Inhibition of macrophage-stimulating protein receptor (ron) and methods of treatment thereof
WO2005086836A3 (en) Ion channel modulators
WO2010003520A3 (en) Anti-tumor immunotherapy
WO2005086895A3 (en) Ion channel modulators
WO2008112290A3 (en) Use of ephb4 as a diagnostic marker and a therapeutic target for ovarian cancer
TNSN08400A1 (en) Organic compounds and their uses
WO2010048026A3 (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
WO2007146335A3 (en) Compounds and compositions for treatment of cancer
WO2005086902A3 (en) Ion channel modulators
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2005097112A3 (en) Ion channel modulators

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007798461

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07798461

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU